A Real-World, multicentre retrospective study to evaluate the clinical performance and safety of MantraTM Surgical Robotic System for soft tissue surgeries.
The purpose of this retrospective study is to evaluate the clinical performance and safety of the Mantra™ Surgical Robotic System, Model 3.0, for soft tissue surgeries. It aims to provide real-world evidence on the system's reliability, safety, and effectiveness in the real world population. The SSI Mantra 3.0 Surgical Robotic System is an advanced, modular, and cost-effective robotic-assisted surgical platform designed to enhance precision, flexibility, and control in minimally invasive surgeries (MIS).
The objective of this retrospective study is to assess the clinical performance and safety of the Mantra™ Surgical Robotic System in performing various soft tissue surgeries based on retrospective data analysis.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
\- Participants must meet all of the following criteria to be eligible for inclusion in this retrospective clinical study of the SSI Mantra 3.0 Surgical Robotic System.
Patients who have previously undergone surgery using the Mantra™ Surgical Robotic System (Model 3.0) for the following procedures mentioned in Appendix D
Exclusion Criteria:
* Patients with missing data on primary endpoints.
Primary outcome measure(s)
Rate of Unplanned Conversion to other minimally invasive surgery (MAS) or open surgery (OP) — 1 day • Rate of Unplanned Conversion to other minimally invasive surgery (MAS) or open surgery (OP).
Successful completion of procedures without the need for conversion — 1 day Successful completion of procedures without the need for conversion
Rate of intraoperative and postoperative serious adverse events (SAEs) occurring up to 30 days post-procedure — 30 days Rate of intraoperative and postoperative serious adverse events (SAEs) occurring up to 30 days post-procedure
Evaluation of surgical complications, including infections, haemorrhage, and device-related adverse events — 30 day Evaluation of surgical complications, including infections, haemorrhage, and device-related adverse events
Trial sites (1)
Facility
City
Region
Status
ASTER CMI Hospital
Bangalore
Karnataka
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.